Related Experiment Video
Updated: Jun 3, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
1Department of Internal Medicine, Des Moines University, USA.
Objective:
To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.
Methods:
A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using the terms "insulin analogs," "insulin detemir" and "long-acting insulin analog."
Results:
Insulin detemir improves glycemic control, based on HbA(1C) reduction and fasting glucose levels, without increasing the risk of hypoglycemia and weight gain. Insulin detemir has lower glycemic variability, with less intra-subject variability in blood glucose levels in patients with type 1 and type 2 diabetes, without increasing the risk of hypoglycemia. When added to oral anti-diabetes agents (OADs) in type 2 diabetes, insulin detemir demonstrates superiority to other basal insulin options.
Conclusion:
Insulin detemir appears to provide better glycemic control with a lower risk of hypoglycemia and less weight gain in the treatment of patients with type 1 and type 2 diabetes.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Type II Diabetes I: Introduction
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Type 2 and Gestational